Archive: July 2012
Highlights in Anti–Tumor Necrosis Factor Monitoring
William J. Sandborn, MD
Special Reporting on:
• Novel Infliximab and Antibody-to-Infliximab Assays Are Predictive of Disease Activity in Patients with Crohn’s Disease
• Antibodies to Infliximab Can Either Be Persistent or Transient: A Retrospective Case-Control Study in IBD Patients Treated with Infliximab Maintenance Therapy
• Putting It Together: Drug Levels and Disease Activity to Tailor Therapy
• Infliximab Concentration and Clinical Outcome in Patients with Ulcerative Colitis